FINNENCE ▪ THE WIRE FILE
THE WIRE · № 60918
Company■ Unclear/unknown
Phase 3 results posted: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis — Abcuro, Inc.
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-01 12:00 UTC
LAST UPDATE2026-10-01 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Completed Phase 3 results for a myositis drug could support a future filing, but no efficacy data is given.
Clinical readout with undisclosed efficacy
CATALYST TO WATCH
Full data disclosure and regulatory filing
MAIN RISK
Results may not support approval
FULL DISPATCH
Sponsor: Abcuro, Inc.; Status: Completed; Conditions: Inclusion Body Myositis; Interventions: ABC008; Enrollment: 272 (actual); First posted: 2023-02-10; Results posted: 2026-10-01; NCT: NCT05721573
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Quadria-backed Maxivision confidentially files for India IPO2026-10-01 23:00 UTC
Quadria-backed Maxivision confidentially files for India IPO2026-10-01 23:00 UTC
→CORRELATIONshares Healthcare
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 17:58 UTC
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 17:58 UTC
←CORRELATIONshares Healthcare
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 20262026-10-01 11:30 UTC
New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 20262026-10-01 11:30 UTC
←CORRELATIONshares Healthcare
Breakingviews - COMMENTARY: Sanofi’s Regeneron fix requires extra shot of M&A2026-10-01 11:42 UTC
Breakingviews - COMMENTARY: Sanofi’s Regeneron fix requires extra shot of M&A2026-10-01 11:42 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy — Amgen2026-10-01 12:00 UTC
New Phase 3 trial: A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy — Amgen2026-10-01 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer — AstraZeneca2026-10-01 12:00 UTC
New Phase 3 trial: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer — AstraZeneca2026-10-01 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.